These model agreements apply to health services in England, Northern Ireland, Scotland and Wales; they replace the 2011 country versions. The accompanying guidelines provide more general information, an overview of changes from the 2011 versions, and additional information on how models should be used and under what circumstances. Feedback on the use of MICRA is welcome to support its future development. Electronic comments in firstname.lastname@example.org The Clinical Trial Agreement for biopharmaceutical industry sponsored research in primary care (Primary Care mCTA) has been developed and approved by the Association of the British Pharmaceutical Industry, the BioIndustry Association, a number of highly active research generalists, the British Medical Association, the Medical Protection Society and uk health authorities. The Health Research Authority (HRA) supports the application of standard agreements. Contracts and agreements can be concluded at many levels; Both inside and outside, both legally and legally. For example, when our member organizations provide grants through an open competition, their “direct” costs for clinical research in the NHS can be borne by NIHR Clinical Research Networks under the “Health and Social Care Research and Development Cost Attributes( (AcoRD) agreement developed by the Department of Health and Social Care (AcoRD). Under the AcoRD agreement, AMRC financiers are not required to pay: nationally approved location-based agreements help speed up the process of awarding industry-sponsored trials to the NHS, as the need for site-by-site audits and local legal agreements is not necessary. This allows studies to start earlier, improve the speed of industry-sponsored clinical trials and enable patients with NHS to access innovative treatments more quickly. The range of model location agreements is supported by guidelines that specify the objectives and modalities of the use of the agreement in the development of clinical research contracts supported by pharmaceutical, biopharmaceutical or medical companies.